Preventing a Transcription Factor from Making Trouble in Leukemia (image) Cold Spring Harbor Laboratory Share Print E-Mail Caption Some subtypes of the AML form of leukemia depend heavily on the activity of MEF2C, a protein that regulates various genes. Cancer cells prevent HDAC4 from epigenetically modifying MEF2C, which would shut it down. Vakoc lab's CRISPR screens helped identify two enablers of this pathology in cancer cells: kinases LKB1 and SIK3, which can be targeted with drugs, restoring the ability of HDAC4 to shut down MEF2C. Credit Vakoc Lab, CSHL Usage Restrictions None Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.